Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex

News

PBAC a lottery for rare diseases

Posted May 7 2021 PM

A string of specialist pharma companies working mainly in the area of rare diseases have told a parliamentary inquiry that the current PBAC system has forced them to try and "pick a winner" when deciding which drugs they should attempt to seek reimbursement for - rather than weighing the needs of patients. 

The Zimmerman inquiry into the approvals process of new medicines and novel medical technologies has also heard companies often don't properly consider bringing drugs to Australia because our reimbursement system is considered too hard and too costly to navigate.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Could access probe be for nothing?
Significant industry participation but what outcome?
Approvals Action
Injectable antibiotic ticked
Fresenius Kabi adds to Gram-positive options